

References

REFERENCES

- Agalioti T, Chen G, Thanos D (2002). Deciphering the transcriptional histone acetylation code for a human gene. *Cell* **111**: 381-392
- Akiyama Y, Maesawa C, Ogasawara S, Terashima M, Masuda T (2003). Celltype-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells. *Am J Pathol* **163**:1911-1919.
- Antequera F, Bird A (1993) CpG islands. *EXS* **64**: 169-185.
- Antequera F, Bird A (1993) Number of CpG islands and genes in human and mouse. *Proc Natl Acad Sci U S A* **90**: 11995-11999.
- Asch BB, Barcellos-Hoff MH, (2001). Epigenetics and breast cancer. *Journal of Mammary Gland Biology and Neoplasia* **6** (2), 151–152.
- Ásgeirsson KS, Jónasson JG, Tryggvadóttir L, Ólafdóttir K, Sigurgeirsdóttir JR, Ingvarsson S, Ögmundsdóttir HM (2000). Altered expression of E-cadherin in breast cancer: patterns, mechanisms and clinical significance. *Eur J Cancer* **36**: 1098-1106.
- Ásgeirsson KS, Jónasson JG, Tryggvadóttir L, Ólafdóttir K, Sigurgeirsdóttir JR, Ingvarsson S, Ögmundsdóttir HM (2000). Altered expression of E-cadherin in breast cancer: patterns, mechanisms and clinical significance. *Eur J Cancer* **36**: 1098-1106.
- Bachman KE (2003). Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. *Cancer Cell* **3**: 89-95.
- Bae YK, Brown A, Garrett E, Bornman D, Fackler MJ, Sukumar S, Herman JG, Gabrielson E, (2004). Hypermethylation in histologically distinct classes of breast cancer. *Clinical Cancer Research* **10** (18), 5998–6005.
- Bae YK, Brown A, Garrett E, Bornman D, Fackler MJ, Sukumar S, Herman JG, Gabrielson E (2004). Hypermethylation in histologically distinct classes of breast cancer. *Clinical Cancer Research* **10**: 5998–6005.
- Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM (1987). Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. *J Virol* **61**: 962-967.

- Bal A, Verma S, Joshi K, Singla A, Thakur R, et al (2012). BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression. *Virchows Arch* **461**: 305–312.
- Baylin SB and Herman JG (2000). DNA hypermethylation in tumorigenesis: epigenetics joins genetics. *Trends Genet.*, **16**: 168–174,
- Baylin SB, Herman JG, Graff JR, Vertino PM, Issa J-PJ (1998). Alterations in DNA methylation a fundamental aspect of neoplasia. *Adv Cancer Research* **72**: 141–96.
- Bedford MT, van Helden PD (1987). Hypomethylation of DNA in pathological conditions of the human prostate. *Cancer Research* **47**: 5274-5276,
- Belinsky SA, Nikula KJ, WAP (1998). Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. *Proc Natl Acad Sci USA* **95**: 11891–6.
- Bender CM, Zingg JM, Jones PA (1998). DNA methylation as a target for drug design. *Pharm Res* **15**: 175-187,
- Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC (2009). Early breast cancer. *Lancet* **373**: 1463-79.
- Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM *et al* (2004). Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. *Ann Oncol* **15**: 875-84.
- Berman H, Zhang J, Crawford YG, Gauthier ML, Fordyce CA, McDermott KM, Sigaroudinia M, Kozakiewicz K, Tlsty TD (2005). Genetic and epigenetic changes in mammary epithelial cells identify a subpopulation of cells involved in early carcinogenesis. *Cold Spring Harb Symp Quant Biol* **70**: 317–327
- Bestor TH (2005). Transposons reanimated in mice. *Cell* **122**: 322-5.
- Bestor TH, Laudano A, Mattaliano R, Ingram V (1988). Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxylterminal domain of the mammalian enzyme is related to bacterial restriction methyltransferases. *J. Mol. Biol.* **203**: 971–83
- Biglia N, Mariani L, Sgro L, Mininanni P, Moggio G, Sismondi P (2007). Increased incidence of lobular breast cancer in women treated with hormone replacement therapy:

implications for diagnosis, surgical and medical treatment. *Endocr Relat Cancer* **14**: 549-67.

Bird AP (1986). CpG-rich islands and the function of DNA methylation. *Nature* **321**: 209-213.

Bloom HJ, Richardson WW (1957). Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. *Br J Cancer* **11**: 359-77.

Bodey B (2002). Cancer-testis antigens: promising targets for antigen directed anti-neoplastic immunotherapy. *Expert Opin Biol Ther* **2**: 577-84.

Breast Cancer Screening. Lyon, France: International Agency for Research on Cancer; 2002.

Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM & Schalken JA (1993). Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. *Cancer Research* **53**: 3241-3245.

Butcher LM, Beck S (2008). Future impact of integrated highthroughput methylome analyses on human health and disease. *J Genet Genomics* **35 (7)**: 391-401

Caldeira JR, Prando EC, Quevedo FC, Moraes Netto FA, Rainho CA, Rogatto SR (2006) CDH1 promoter hypermethylation and Ecadherin protein expression in infiltrating breast cancer. *BMC Cancer* **6 (1)**: 48

Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB (1999). Synergy of demethylation and histone deacetylase inhibition in the reexpression of genes silenced in cancer. *Nat Genet* **21**: 103-7.

Catteau A, Harris WH, Xu CF, Solomon E (1999). Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. *Oncogene* **18**: 1957-1965.

Catteau A, Morris JR (2002). BRCA1 methylation: A significant role in tumour development? *Semin Cancer Biol* **12**: 359-371.

Chaffanet M, Gressin L, Preudhomme C, Soenen-Cornu V, Birnbaum D, Pebusque MJ (2000). MOZ is fused to p300 in an acute monocytic leukemia *Genes Chromosomes Cancer* **28**: 138-144.

- Chakravarthy S, Park YJ, Chodaparambil J, Edayathumangalam RS & Luger K (2005). Structure and dynamic properties of nucleosome core particles. *FEBS Lett* **579**: 895-898.
- Chen T, Ueda Y, Dodge JE, Wang Z, Li E. (2003). Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. *Mol. Cell Biol.* **23**: 5594–605
- Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE (2003). Inhibition of DNA methylation and reactivation of silenced genes by zebularine. *J Natl Cancer Inst* **95**: 399–409.
- Chopra R (2001). The Indian scene. *Journal of Clinical Oncology* **19** (18 Suppl): 106S–111S.
- Chopra, R (2001). The Indian scene. *Journal of Clinical Oncology* **19**: 106S–111S.
- Christman JK (2002). 5-Azacytidine and 5-aza-2-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. *Oncogene* **21**: 5483–95.
- Claes K, Machackova E, De Vos M, Mortier G, De Paepe A, Messiaen L (1999). Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 Flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. Mutations in brief no. 224. Online. *Hum Mutat* **13**: 256.
- Clark SJ, Melki J (2002) DNA methylation and gene silencing in cancer: which is the guilty part? *Oncogene* **21**: 5380-5387.
- Claus EB, Risch N, Thompson WD (1991). Genetic analysis of breast cancer in the cancer and steroid hormone study. *Am J Hum Genet* **48**: 232-42.
- Clavel-Chapelon F (2002). Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. *Br J Cancer* **86**: 723-7.
- Cleton-Jansen AM, Moerland EW, Kuipers-Dijkshoorn NJ, Callen DF, Sutherland GR, Hansen B, Devilee P & Cornelisse CJ (1994). At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer. *Genes, Chromosomes and Cancer* **9**: 101–107.

- Cleveland RJ, Eng SM, Abrahamson PE, Britton JA, Teitelbaum SL, Neugut AI *et al* (2007). Weight gain prior to diagnosis and survival from breast cancer. *Cancer Epidemiol Biomarkers Prev* **16**: 1803-11.
- Cohen LA, Amin S, Marks PA, Rifkind RA, Desai D, Richon VM (1999). Chemoprevention of carcinogen-induced mammary tumorigenesis by hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). *Anticancer Research* **19**: 4999–5005.
- Cohen LA, Marks PA, Rifkind RA, Amin S, Desai D, Pittman B (2002). Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. *Anticancer Research* **22**: 1497–504.
- Colditz GA, Willett WC, Hunter DJ, Stampfer MJ, Manson JE, Hennekens CH *et al* (1993). Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. *JAMA* **270**: 338-43.
- Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Mazzarol G, Pruneri G *et al* (2005). Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. *J Clin Oncol* **23**: 1379-89.
- Colot V, Rossignol JL (1999). Eukaryotic DNA methylation as an evolutionary device. *Bioessays* **21**: 402-411.
- Cote S, Momparler RL (1997). Activation of the retinoic acid receptor beta gene by 5-aza-2_-deoxycytidine in human DLD-1 colon carcinoma cells. *Anticancer Drug* **8**: 56–61.
- Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L *et al* (1997). BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. *N Engl J Med* **336**: 1409-15.
- Coulondre C, Miller JH, Farabagh PJ, Gilbert W (1978). Molecular basis of base substitution hotspots in Escherichia coli. *Nature* **274**: 775–780.
- Dammann R, Yang G, Pfeifer GP (2001). Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. *Cancer Research* **61**: 3105–9.
- D'Andrea MR, Limiti MR, Bari M, Zambenedetti P, Montagutti A, Ricci F, Pappagallo GL, Sartori D, Vinante O, Mingazzini PL (2007). Correlation between genetic and

biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. *Breast Cancer Research Treat* **101**: 279-284.

Daniel JA, Pray-Grant MG, Grant PA (2005). Effector proteins for methylated histones: an expanding family. *Cell Cycle* in press.

Davie JR (1998). Covalent modifications of histones: expression from chromatin templates. *Curr Opin Genet Dev* **8**: 173-178.

Davis CD, Uthus EO (2002). Dietary selenite and azadeoxycytidine treatments affect dimethylhydrazine-induced aberrant crypt formation in rat colon and DNA methylation in HT-29 cells. *J Nutr* **132**: 292-7.

Davis S, Mirick DK, Stevens RG (2001). Night shift work, light at night, and risk of breast cancer. *J Natl Cancer Inst* **93**: 1557-62.

de Bustros A, Nelkin BD, Silverman A, Ehrlich G, Poiesz B, Baylin SB (1988). The short arm of chromosome 11 is a "hot spot" for hypermethylation in human neoplasia. *Proc Natl Acad Sci U S A* **85**: 5693-5697.

de la Cruz X, Lois S, Sánchez-Molina S, Martínez-Balbas MA (2005). Do protein motifs read the histone code? *Bioessays* **27**: 164-175.

De Marzo AM, Marchi VL, Yang ES, Veeraswamy R, Lin X, Nelson WG (1999). Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis. *Cancer Research* **59**: 3855-3860.

Desai D, Das A, Cohen L, El-Bayoumy K, Amin S (2003). Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. *AntiCancer Research* **23**: 499-503.

Devesa SS, Diamond EL (1980). Association of breast cancer and cervical cancer incidence with income and education among whites and blacks. *J Natl Cancer Inst* **65**: 515-28.

Di Croce L, Raker VA, Corsaro M (2002). Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. *Science* **295**: 1079-1082.

- Douglas DB, Akiyama Y, Carraway H, Belinsky SA, Esteller M, Gabrielson E, Weitzman S, Williams T, Herman JG, Baylin SB (2004). Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast cancer. *Cancer Res* **64(5)**: 1611–1620
- Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P (2004). Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. *Clinical Cancer Research* **10 (18)**: 6189–6193.
- Dunn BK (2003). Hypomethylation: one side of a larger picture. *Ann N Y Acad Sci* **983**: 28–42.
- Dupont WD, Page DL (1985). Risk factors for breast cancer in women with proliferative breast diseases. *N engl J Med*, **312**: 146-151.
- Easton DF, Ford D, Bishop DT (1995). Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. *Am J Hum Genet* **56**: 265-71.
- Ed. Zaridze DG (2000). *Kantserogenez* (Carcinogenesis). Moscow: Nauchnyi Mir.
- Eden A, Gaudet F, Waghmare A, Jaenisch R (2003). Chromosomal instability and tumors promoted by DNA hypomethylation. *Science* **300**: 455.
- Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. *Nature* **429**: 457-463.
- Ehrlich M (2002). DNA hypomethylation, cancer, the immunodeficiency, centromeric region instability, facial anomalies syndrome and chromosomal rearrangements. *J Nutr* **132**: 2424S-2429S.
- Ehrlich M (2002). DNA methylation in cancer: Too much, but also too little. *Oncogene* **21**: 5400- 5413.
- Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG (1999). Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. *Cancer Research* **59 (1)**: 67–70.
- Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, et al (2000). Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. *J Natl Cancer Inst* **92**: 564–569.

Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, (2000). Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. *Cancer Research* **60**: 4366–71.

Esteller M., Corn P., Baylin S., Herman J (2001). A gene hypermethylation profile of human cancer. *Cancer Res.* **61**: 3225–3229.

Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, (2001). Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. *Lancet* **357**: 1335–6.

Fahrner JA, Eguchi S, Herman JG (2002). Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. *Cancer Research* **62**: 7213-7218.

Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer S.L, Salisbury J.D, Cheng AS, Li L, Abbosh PH, Huang TH, Nephew KP (2006). Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. *Cancer Research* **66 (24)**, 11954–11966.

Feinberg AP, Cui H, Ohlsson R (2002). DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. *Semin Cancer Biol* **12**: 389- 98.

Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M (1988). Reduced genomic 5-methylcytosine content in human colonic neoplasia. *Cancer Research* **48**: 1159-1161.

Feinberg AP, Vogelstein B (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. *Nature* **301**: 89-92.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* **127**: 2893-917.

Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, (2001). Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. *Cancer Research* **61**: 2–7.

Feuer, E.J., Wun, L.M., Boring, C.C., Flanders, W.D., Timmel, M.J., Tong, T., (1993). The lifetime risk of developing breast cancer. *Journal of the National Cancer Institute* **85 (11)**: 892–897.

Fiala ES, Staretz ME, Pandya GA, El-Bayoumy K, Hamilton SR (1998). Inhibition of DNA cytosine methyltransferase by chemopreventive selenium compounds, determined

by an improved assay for DNA cytosine methyltransferase and DNA cytosine methylation. *Carcinogenesis* **19**: 597–604.

Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI *et al* (1998). Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. *Am J Hum Genet* **63**: 45-51.

Fong M, Henson DE, Devesa SS, Anderson WF (2006). Inter- and intra-ethnic differences for female breast carcinoma incidence in the continental United States and in the state of Hawaii. *Breast Cancer Research Treat* **97**: 57–65.

Foster SA, Wong DJ, Barrett MT, Galloway DA (1998). Inactivation of p16 in human mammary epithelial cells by CpG island methylation. *Molecular and Cellular Biology* **18**: 1793–1801.

Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B, Casey G *et al* (1997). Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. *Am J Hum Genet* **60**: 313-9.

Frommer M, McDonald LE, Millar DS, Collis CM, WATT F, Grigg GW, Molloy PL and Paul CL (1992). A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. *Proc. Natl. Acad. Sci. USA* **89**: 1827-1831.

Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, Hotta K, Kozuki T, Aoe M, Kiura K, Ueoka H, Tanimoto M, (2005). Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. *Clinical Cancer Research* **11 (3)**: 1219–1225.

Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R *et al* (2004). A census of human cancer genes. *Nat Rev Cancer* **4**: 177-83.

Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S *et al* (1994). BRCA1 mutations in primary breast and ovarian carcinomas. *Science* **266**: 120-2.

Futscher BW, Oshiro MM, Wozniak RJ (2002). Role for DNA methylation in the control of cell type specific maspin expression. *Nat Genet* **31**: 175-9.

Gallin WJ, Sorkin BC, Edelman GM and Cunningham BA (1987). Sequence analysis of a cDNA clone encoding the liver cell adhesion molecule, L-CAM. *Proc Natl Acad Sci USA*, **84**: 2808-2812.

- Gamma-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, Ehrlich M (1983) The 5-methylcytosine content of DNA from human tumors. *Nucleic Acids Res*, **11**: 6883-6894.
- Garber K (2002). Breaking the silence: the rise of epigenetic therapy. *J Natl Cancer Inst* **94**: 874–5.
- Garber K. Synthetic lethality (2002): killing cancer with cancer. *J Natl Cancer Inst* **94**: 1666–8.
- Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW (2003). Induction of tumors in mice by genomic hypomethylation. *Science* **300**: 489–92.
- Geiman TM, Robertson KD (2001). Chromatin remodeling, histone modifications, and DNA methylation- how does it all fittogether? *Cell Biochem* **87**: 117-125.
- Giacinti L, Claudio PP, Lopez M, Giordano A (2006). Epigenetic information and estrogen receptor alpha expression in breast cancer. *Oncologist* **11 (1)**: 1–8.
- Giordano SH, Buzdar AU, Hortobagyi GN (2002). Breast cancer in men. *Ann Intern Med* **137**: 678-87.
- Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP (1985). Hypomethylation of DNA from benign and malignant human colon neoplasms. *Science*, **228**: 187-190.
- Goffin J, Eisenhauer E (2002). DNA methyltransferase inhibitors-state of the art. *Ann Oncol* **13**: 1699–716.
- Golubicic I, Borojevic N, Pavlovic T (2008). Risk factors for breast cancer: is ionizing radiation among them? *J BUON* **13**: 487-94.
- Graff JR (2000). Aberrant methylation of the estrogen receptor and E-cadherin 5'CpG islands increases with malignant progression in breast cancer *Cancer Res* **60**: 4346-4348.
- Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE & Baylin SB 1995 E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. *Cancer Research* **55**: 5195–5199.
- Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B (1989). Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. *Hum Genet* **83**: 155-158.

- Gumbiner BM (1996). Cell adhesion: The molecular basis of tissue architecture and morphogenesis. *Cell*, **84**: 345-357.
- Ha M, Mabuchi K, Sigurdson AJ, Freedman DM, Linet MS, Doody MM *et al* (2007). Smoking cigarettes before first childbirth and risk of breast cancer. *Am J Epidemiol* **166**: 55-61.
- Hansen RS, Wijmenga C, Luo P, Stanek AM, Canfield TK, Weemaes CM, Gartler SM (1999). The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. *Proc Natl Acad Sci U S A*, **96**: 14412-14417.
- Hedau S, Jain N, Husain SA, Mandal AK, Ray G, Shahid M *et al* (2004). Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. *Breast Cancer Res Treat* **88**: 177-86.
- Herman JG, Graff JR, Myohanen S, Nelkin BD, and Baylin S B (1996) Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. *Proc. Natl. Acad. Sci. USA* **93**: 9821-9826,
- Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D & Baylin SB (1995) Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. *Cancer Research* **55**: 4525–4530.
- Herman JG, Umar A, Polyak K (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. *Proc Natl Acad Sci USA* **95**: 6870–6875.
- Hermann A, Schmitt S, Jeltsch A. (2003). The human Dnmt2 has residual DNA-(cytosine-C5) methyltransferase activity. *J. Biol Chem* **278**: 31717–21
- Hewitt M, Breen N, Devesa S (1999). Cancer prevalence and survivorship issues: analyses of the 1992 National Health Interview Survey. *J Natl Cancer Inst* **91**: 1480–1486.
- Hibi K, Robinson CR., Booker S, Wu L, Hamilton SR, Sidransky D, Jen J (1998). Molecular detection of genetic alterations in the serum of colorectal cancer patients. *Cancer Research* **58 (7)**: 1405–1407.
- Hiraguri S, Godfrey T, Nakamura H, Graff J, Collins C, Shayesteh L, Doggett N, Johnson K, Wheelock M, Herman J, Baylin S, Pinkel D & Gray J 1998 Mechanisms of inactivation of E-cadherin in breast cancer cell lines. *Cancer Research* **58**: 1972–1977.

Hobbs CA, Paul BA, Gilmour SK (2002). Deregulation of polyamine biosynthesis alters intrinsic histone acetyltransferase and deacetylase activities in murine skin and tumors. *Cancer Research* **62**: 67–74.

Holst CR, Nuovo GJ, Esteller M, Chew K, Baylin SB, Herman JG, and Tlsty TD (2003). Methylation of p16 (INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. *Cancer Research* **63**: 1596–1601.

Hoque MO, Begum S, Topaloglu O, Jeronimo C, Mambo E, Westran WH, Califano JA, Sidransky D (2004). Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine and serum DNA of patients with renal cancer. *Cancer Research* **64(15)**: 5511–5517.

Hu XC, Wong IH, Chow LWC (2003). Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications. *Oncol Rep* **10**: 1811–1815.

Hui R, Macmillan RD, Kenny FS, Musgrove EA, Blamey RW, Nicholson RI, Robertson JF & Sutherland RL (2000). INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. *Clinical Cancer Research* **6**: 2777–2787.

Hwang-Verslues WW, Kuo WH, Chang PH, Pan CC, Wang HH, Tsai ST *et al* (2009). Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. *PLoS One* **4**: e8377.

Ibanez de Caceres I, Battagli, C, Esteller M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg BL, Cairns P (2004). Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. *Cancer Research* **64 (18)**: 6476–6481.

Ichikawa D, Koike H, Ikoma H, Ikoma D, Tani N, Otsuji E, Kitamura K, Yamagishi H, (2000). Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer. *AntiCancer Research* **24(4)**: 2477–2481.

Ilyas M & Tomlinson IP (1997). The interactions of APC, E-cadherin and beta-catenin in tumour development and progression. *Journal of Pathology* **182**: 128–137.

Indian Council of Medical Research, New Delhi. National Cancer registry Programme (2001). Consolidated Report of the Population Based Cancer Registries. 1990–1996.

- Jablonka E, Lamb MJ (2002). The changing concept of epigenetics. *Ann N Y Acad Sci*, **981**: 82-96.
- Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK (1999). Significance of axillary lymph node metastasis in primary breast cancer. *J Clin Oncol* **17**: 2334-40.
- Jemal A, Clegg LX, Ward E (2004). Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. *Cancer* **101**: 3–27.
- Jerônimo C, Costa I, Martins MC, Monteiro P, Lisboa S, Palmeira C, Henrique R, Teixeira MR, Lopes C (2003). Detection of gene promoter hypermethylation in fine needle washings from breast lesions. *Clin Cancer Res* **9**: 3413-3417.
- Jhaveri MS, Morrow CS (1998). Methylation-mediated regulation of the glutathione S-transferase P1 gene in human breast cancer cells. *Gene* **210(1)**: 1–7
- Jin Z, Tamura G, Tsuchiya T (2001). Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. *Br J Cancer* **85**: 69–73.
- Johnstone RW (2002). Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. *Nat Rev Drug Discovery* **1**:287–99.
- Jones PA, Baylin SB (2002). The fundamental role of epigenetic events in cancer. *Nat Rev Gen* **3**: 415–428.
- Jones PA, Laird PW (1999). Cancer epigenetics comes of age. *Nat Genet* **21**: 163–7.
- Kane MF, Loda M, Faida GM, et al (1997). Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repairdefective human tumor cell lines. *Cancer Research* **57**: 808–811.
- Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA (2004). Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. *Mol Pharmacol* **65**: 18-27.
- Key TJ, Verkasalo PK, Banks E (2001). Epidemiology of breast cancer. *Lancet Oncol* **2**: 133-40.
- Kim D-H, Nelson HH, Wiencke JK (2001). *p16/INK4A* and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small lung cancer. *Cancer Res.* **61**: 3419–3424.

- Kim GD, Ni J, Kelesoglu N, Roberts RJ, Pradhan S (2002). Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. *EMBO J.* **21**: 4183–95
- Kim YI, Giuliano A, Hatch KD, Schneider A, Nour MA, Dallal GE (1994). Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma. *Cancer* **74**: 893–9.
- Kishimoto M, Kohno T, Okudela K, Otsuka A, Sasaki H, Tanabe C, Sakiyama T, HIRAMA C, Kitabayashi I, Minna JD, Takenoshita S, Yokota J (2005). Mutations and deletions of the CBP gene in human lung cancer. *Clin Cancer Research* **11**: 512-519.
- Koike H, Ichikawa D, Ikoma H, Tani N, Ikoma D, Otsuji E, Okamoto K, Ueda Y, Kitamura K, Yamagishi H (2005). Comparison of serum aberrant methylation and conventional tumor markers in gastric cancer patients. *Hepato-gastroenterology* **52 (64)**: 1293–1296.
- Koshiishi N, Chong JM, Fukasawa T, Ikeno R, Hayashi Y, Funata N, Nagai H, Miyaki M, Matsumoto Y, Fukayama M (2004). p300 Gene alterations in intestinal and diffuse types of gastric carcinoma. *Gastric Cancer*, **7**: 85-90.
- Krop IE, Sgroi D, Porter DA, Lunetta KL, LeVangie R, Seth P, Kaelin CM, Rhei E, Bosenberg M, Schnitt S (2001). HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. *Proc Natl Acad Sci USA* **98(17)**: 9796– 9801
- Kuo MH, Allis CD (1998). Roles of histone acetyltransferases and deacetylases in gene regulation. *Bioessays* **20**: 615-626.
- Lachner M, O'Carroll D, Rea S, Mechtler K, Jenuwein T (2001) Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. *Nature*, **410**: 116-120.
- Laird PW (2003). The power and the promise of DNA methylation markers. *Nat Rev* **3**: 253–266
- Laird PW (2003). The power and the promise of DNA methylation markers. *Nat Rev Cancer* **3**: 253–66.
- Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E (1995). Suppression of intestinal neoplasia by DNA hypomethylation. *Cell* **81**: 197–205.
- Laird PW, Jaenisch R: DNA methylation and cancer. *Human Molecular Genetics* 1994, **3**: 1487-1495.

- Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C *et al* (1996). BRCA2 mutations in primary breast and ovarian cancers. *Nat Genet* **13**: 238-40.
- Lantry LE, Zhang Z, Crist KA, Wang Y, Kelloff GJ, Lubet RA (1999) . 5-Aza-2-deoxycytidine is chemopreventive in a 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model. *Carcinogenesis* **3**: 43–6.
- Lapidus RG, Nass SJ, Butash KA, Parl FF, Graff JR, Herman JG, Davidson NE (1998). Mapping of the ER gene CpG island methylation by methylation-specific polymerase chain reaction. *Cancer Research* **58**: 2515-2519.
- Lea MA, Randolph VM, Lee JE, desBordes C (2001). Induction of histone acetylation in mouse erythroleukemia cells by some organosulfur compounds including allyl isothiocyanate. *Int J Cancer* **92**: 784–9.
- Lee WH, Morton RA, Epstein JI (1994). Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. *Proc Natl Acad Sci USA* **91**: 11733–11737.
- Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H (2002). Quantitative assessment of promoter hypermethylation during breast cancer development. *American Journal of Pathology* **160** (2): 605–612.
- Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977). Free DNA in the serum of cancer patients and the effect of therapy. *Cancer Research* **37** (3): 646–650.
- Leu YW, Yan PS, Fan M (2004). Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. *Cancer Research* **64**: 8184–8192.
- LeungWK, To KF, Chu ES, Chan MW, Bai AH, Ng EK, Chan FK, Sung JJ (2005). Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. *British Journal of Cancer* **92** (12): 2190–2194.
- Lewis CM, Cler LR, Bu DW, Zochbauer-Muller S, Milchgrub S, Naftalis EZ, Leitch AM, Minna JD, Euhus DM (2005). Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. *Clin Cancer Research* **11**(1): 166–172
- Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z *et al* (1997). Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. *Nat Genet* **16**: 64-7.

- Licht JD (2001). AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. *Oncogene* **20**:5660-5679.
- Liggett WH Jr & Sidransky D (1998). Role of the p16 tumor suppressor gene in cancer. *Journal of Clinical Oncology* **16**: 1197–1206.
- Lin CH, Hsieh SY, Sheen IS (2001). Genome-wide hypomethylation in hepatocellular carcinogenesis. *Cancer Research* **61**: 4238-4243,
- Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM (1998). Role of the histone deacetylase complex in acute promyelocytic leukaemia. *Nature* **391**: 811-814.
- Lin X, Asgari K, Putzi MJ, Gage WR, Yu X, Cornblatt BS (2001). Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. *Cancer Research* **61**: 8611–6.
- Liu K, Wang YF, Cantemir C, Muller MT (2003). Endogenous assays of DNA methyltransferases: evidence for differential activities of DNMT1, DNMT2, and DNMT3 in mammalian cells *in vivo*. *Mol Cell Biol* **23**: 2709-2719.
- Liu L, Wylie RC, Andrews LG, Tollefsbol TO (2003). Aging, cancer and nutrition: the DNA methylation connection. *Mech Ageing Dev* **124**: 989-998.
- Luo J, Margolis KL, Wactawski-Wende J, Horn K, Messina C, Stefanick ML *et al* Association of active and passive smoking with risk of breast cancer among postmenopausal women: a prospective cohort study. *BMJ* **342**: d1016.
- Lynch BM, Neilson HK, Friedenreich CM Physical activity and breast cancer prevention. *Recent Results Cancer Res* **186**: 13-42.
- Lynch BM, Neilson HK, Friedenreich CM Physical activity and breast cancer prevention. *Recent Results Cancer Res* **186**: 13-42.
- Lynch P, Winn RJ (1989). Clinical management of hereditary nonpolyposis colon cancer. High-risk clinics and registries. *Hematol Oncol Clin North Am* **3**: 75-86.
- Lynch P, Winn RJ (1989). Clinical management of hereditary nonpolyposis colon cancer. High-risk clinics and registries. *Hematol Oncol Clin North Am* **3**: 75-86.
- Macaluso M, Montanari M, Cinti C, Giordano A (2005). Modulation of cell cycle components by epigenetic and genetic events. *Seminars in Oncology* **32** (5): 452–457.

- MacMahon B (2006). Epidemiology and the causes of breast cancer. *Int J Cancer* **118**: 2373-8.
- Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN (1995). Proportion of breast cancer cases in the United States explained by well-established risk factors. *J Natl Cancer Inst* **87**: 1681-5.
- Mahadevan LC, Willis AC, Barratt MJ (1991). Rapid histone H3 phosphorylation in response to growth factors, phorbol esters, okadaic acid and protein synthesis inhibitors. *Cell* **65**: 775-783.
- Malkin D, Li FP, Strong LC, Fraumeni JF, Jr., Nelson CE, Kim DH *et al* (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science* **250**: 1233-8.
- Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, Hengge UR (2006). Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. *Journal of Investigative Dermatology* **126** (2): 422–431.
- Marks PA, Richon VM, Breslow R, Rifkind RA (2001). Histone deacetylase inhibitors as new cancer drugs. *Curr Opin Oncol*; **13**: 477–83.
- Marshall, F.F., 2005. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. *Journal of Urology* **173** (6): 1918.
- McGregor F, Muntoni A, Fleming J, Brown J, Felix DH, MacDonald DG, *et al* (2002). Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine. *Cancer Res*; **62**: 4757–66.
- Mehrotra J, Ganpat MM, Kanaan Y, Fackler MJ, McVeigh M, *et al.* (2004). Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. *Clin Cancer Research* **10**: 2052–2057.
- Mehrotra J, Ganpat MM, Kanaan Y, Fackler MJ, McVeigh M, Lahti-Domenici J, Polyak K, Argani P, Naab T, Garrett E, Parmigiani G, Broome C, Sukumar S (2004). Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. *Clinical Cancer Research* **10** (6): 2052–2057.

Mehrotra J, Vali M, McVeigh M, Kominsky S.L, Fackler MJ, Lahti-Domenici J, Polyak K, Sacchi N, Garrett-Mayer E, Argani P, Sukumar, S (2004). Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. *Clinical Cancer Research* **10 (9)**: 3104–3109.

Melki JR, Vincent PC, Clark SJ (1999): Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. *Cancer Research* **59**: 3730- 3740,

Melnick A, Carlile G, Ahmad KF, Kiang CL, Corcoran C, Bardwell V, Prive GG, Licht JD (2002). Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. *Mol Cell Biol* **22**:1804-1818.

Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennet LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen Stano A, Katcher H, Yakumo K, Gholami I, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayanath P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis JC, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH (1994). A strong candidate for breast and ovarian cancer susceptibility gene BRCA1. *Science*, **266**: 66-71.

Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S *et al* (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* **266**: 66-71.

Mitika M 2003. Researches seek mammography alternatives. *Journal of the American Medical Association* **290**, 450–451.

Montazeri A, Sadighi J, Farzadi F, Maftoon F, Vahdaninia M, Ansari M *et al* (2008). Weight, height, body mass index and risk of breast cancer in postmenopausal women: a case-control study. *BMC Cancer* **8**: 278.

Mori T, O'Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K, Kuo C, Takeshima TL, Milford R, Wang HJ, Vu VD, Nguyen SL, Hoon DS, (2005). Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. *Journal of Clinical Oncology* **23 (36)**, 9351–9358.

Muller HM, Widschwendter A, Fiegl H, Ivarsson, L, Goebel G, Perkmann E, Marth C, Widschwendter M, (2003). DNA methylation in serum of breast cancer patients: an independent prognostic marker. *Cancer Research* **63 (22)**, 7641–7645.

- Nandakumar A, Ramnath T, Chaturvedi M The magnitude of cancer breast in India: a summary. *Indian Journal of Surgical Oncology* **1**: 8-9.
- Narayan A, Ji W, Zhang XY, Marrogi A, Graff JR, Baylin SB, Ehrlich M (1998). Hypomethylation of pericentromeric DNA in breast adenocarcinomas. *Int J Cancer* **77**: 833-838.
- Nass SJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, Davidson NE & Graff JR (2000). Aberrant methylation of the estrogen receptor and E-cadherin 5'CpG islands increases with malignant progression in human breast cancer. *Cancer Research* **60**: 4346-4348.
- Nguyen CT, Gonzales FA, Jones PA (2002). Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. *Nucleic Acids Res* **29**: 4598-4606.
- Nowak SJ, Corces VG (2000). Phosphorylation of histone H3 correlates with transcriptionally active loci. *Genes Dev*, **14**: 3003-3013.
- Nowell PC (1976). The clonal evolution of tumor cell populations. *Science* **194**: 23-8.
- Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, Li LC, Kawakami T, Urakami S, Ribeiro-Filho LA, Terashima M, Fujime M, Igawa M, Dahiya R (2005). Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. *Clin Cancer Research* **11**: 1028-1036.
- Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, Takatsuka Y, Matsuyoshi N, Hirano S, Takeichi M (1993). Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. *Cancer Research* **53**: 1696-1701.
- Oka H, Shiozaki H, Kobayashi K, Tahara H, Kobayashi T, Takatsuka Y & Mori T (1992). Correlation between E-cadherin expression and metastasis in human breast cancer: preliminary report. *Nippon Geka Gakkai Zasshi* **93** 105.
- Okano M, Bell DW, Haber DA, et al (1999). DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. *Cell* **99**: 247-257

- Okano M, Bell DW, Haber DA, Li E (1999). DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. *Cell* **99**: 247–57
- Okano M, Xie S, Li E. (1998). Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. *Nat. Genet.* **19**: 219–20
- Olsen JH, Hahnemann JM, Borresen-Dale AL, Brondum-Nielsen K, Hammarstrom L, Kleinerman R *et al* (2001). Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. *J Natl Cancer Inst* **93**: 121-7.
- Palacios J, Benito N, Pizarro A, Suarez A, Espada J, Cano A, Gamallo C1995,: Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features. *Am J Pathol* **146**: 605-612.
- Park CH, Lee JH, Yang CH (2005). Curcumin derivatives inhibit the formation of Jun-Fos-DNA complex independently of their conserved cysteine residues. *J Biochem Mol Biol* **38**: 474-80.
- Park S, Lee DK, Yang CH (1998). Inhibition of fos-jun-DNA complex formation by dihydroguaiaretic acid and in vitro cytotoxic effects on cancer cells. *Cancer Lett* **127**: 23-8.
- Park SY, Gonen M, Kim HJ, Michor F, Polyak K Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. *J Clin Invest* **120**: 636-44.
- Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. *CA Cancer J Clin.* **55(2)**: 74-10.
- Parrela P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, Rossiello R, Liguoro G, Seripa D, Gravina C, Rabitti C, Rinaldi M, Nicol T, Tommasi S, Paradiso A, Schittulli F, Altomare V, Fazio VM (2004). Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. *Clin Cancer Res*, **10**: 5349-5354.
- Parrela P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, Rossiello R, Liguoro G, Seripa D, Gravina C, Rabitti C, Rinaldi M, Nicol T, Tommasi S, Paradiso A, Schittulli F, Altomare V, Fazio VM (2004). Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. *Clin Cancer Res* **10**: 349-5354.

- Pascreau G, Arlot-Bonnemains Y, Prigent C (2003). Phosphorylation of histone and histone-like proteins by aurora kinases during mitosis. *Prog Cell Cycle Res* **5**: 369-374.
- Paz MF, Wei S, Cigudosa JC, Rodriguez-Perales S, Peinado MA, et al. (2003). Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. *Hum. Mol. Genet.* **12**: 2209–19.
- Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S *et al* Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. *Cell* **140**: 62-73.
- Prokhortchouk A, Hendrich B, Jorgensen H, et al (2001). The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor. *Genes Dev* **15**: 1613-1618.
- Prokhortchouk E, Hendrich B (2002). Methyl-CpG binding proteins and cancer: Are MeCpGs more important than MBDs? *Oncogene* **21**: 5394-5399.
- Rasbridge SA, Gillett CE, Sampson SA, Walsh FS, Millis RR (1993). Epithelial (E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma. *J Pathol* **169**: 245- 250.
- Reik W, Dean W, Walter J (2001). Epigenetic reprogramming in mammalian development. *Science* **293**: 1089-1093.
- Reik W, Lewis A (2005). Co-evolution of X-chromosome inactivation and imprinting in mammals. *Nat Rev Genet* **6**: 403-10.
- Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, et al. (2004). DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. *Nature* **416**: 552–56
- Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, et al (2002). DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. *Nature* **416**: 552–6.
- Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG, et al (2000). CpG methylation is maintained in human cancer cells lacking DNMT1. *Nature* **404**: 1003–7.
- Risinger JI, Berchuck A, Kohler MF & Boyd J (1994). Mutations of the E-cadherin gene in human gynecologic cancers. *Nature Genetics* **7**: 98–102.
- Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, MacLeod AR (2003). DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. *Nat Genet* **33**: 61-65.

Salmon DJ, Clark GM, Wong SG (1987). Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. *Science* **235**: 177-82.

Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D (2000). Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. *Cancer Research* **60** (4): 892–895.

Santini V, Kantarjian HM, Issa JP (2001). Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. *Ann Intern Med* **134**: 573-586.

Sato N, Maitra A, Fukushima N, Van Heek NT, Matsubayashi H, Iacobuzio-Donahue CA, Rosty C, Goggins M (2003). Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. *Cancer Research* **63**: 4158-4166.

Saxena S, Rekhi B, Bansal A, Bagga A, Chintamani C, Murthy NS (2005). Clinicomorphological patterns of breast cancer including family history in a New Delhi hospital, India—a cross-sectional study. *World Journal of Surgical Oncology* **3**: 67.

Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I *et al* (2001). Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. *J Natl Cancer Inst* **93**: 1563-8.

Sharpless NE & DePinho RA (1999). The INK4A/ARF locus and its two gene products. *Current Opinion in Genetics and Development* **9**: 22–30.

Sherr CJ (1996). Cancer cell cycles. *Science* **274**: 1672–1677.

Shinozaki M, Hoon DS, Giuliano AE (2005). Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. *Clinical Cancer Research* **11**: 2156–2162.

Shinozaki M, Hoon DSB, Giuliano AE, Hansen NM, Wang HJ, Turner R, Taback B (2005). Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. *Clin Cancer Res* **11**: 2156-2162.

Shukla S, Mirza S, Sharma G, Parshad R, Gupta SD, Ralhan R (2006). Detection of RASSF1A and RAR α hypermethylation in serum DNA from breast cancer patients. *Epigenetics* **1** (2): 88–93.

Sidransky D (2002). Emerging molecular markers of cancer. *Nat Rev Cancer* **2**: 210–9.

- Singal R, Ferris R, Little JA, et al (1997). Methylation of the minimal promoter of an embryonic globin gene silences transcription in primary erythroid cells. *Proc Natl Acad Sci U S A* **94**: 13724-13729
- Singal R, Ginder GD (1999). DNA methylation. *Blood* **93**: 4059-4070.
- Singal R, van Wert J, Bashambu M (2001). Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. *Cancer Research* **61**: 4820-4826.
- Sirchia SM, Ferguson AT, Sironi E, Subramanian S, Orlandi R, Sukumar S, et al (2000). Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. *Oncogene* **19**: 1556-63.
- Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, et al (2002). Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. *Cancer Research* **62**: 2455-61.
- So CK, Nie Y, Song Y (2004). Loss of heterozygosity and internal tandem duplication mutations of the CBP gene are frequent events in human esophageal squamous cell carcinoma. *Clin Cancer Research* **10**: 19-27.
- Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, Housman D, Doggett NA, Rowley JD, Zeleznik-Le NJ (1997). MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). *Proc Natl Acad Sci U S A* **94**: 8732-8777.
- Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N, Hundrup YA *et al* (2004). Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. *Int J Cancer* **109**: 721-7.
- Stewart CL, Soria AL, Hamel PA (2001). Integration of the pRb and p53 cell cycle control pathways. *Journal of Neurooncology* **51**, 183-204.
- Strichman-Almashanu LZ (2002). A genome-wide screen for normally methylated human CgG islands that can identify novel imprinted genes. *Genome Res* **12**: 543-554.
- Suzuki M, Shigematsu H, Shivapurkar N, Reddy J, Miyajima K, Takahashi T, Gazdar AF, Frenkel EP (2006). Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer. *Cancer Letters* **242(2)**: 222-30.

- Szyf M, Pakneshan P, Rabbani SA (2004). DNA methylation and breast cancer. *Biochemical Pharmacology* **68** (6): 1187–1197.
- Szyf M, Pakneshan P, Rabbani SA, (2004). DNA demethylation and cancer: therapeutic implications. *Cancer Letters* **211**, 133–143.
- Szyf M, Targeti NG (2003). DNA methylation in cancer. *Ageing Res Rev*, **2**: 299-328.
- Tam SW, Shay JW, and Pagano M (1994).. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. *Cancer Res.*, **54**: 5816–5820,
- Tamaru H, Selker EU (2001). A histone H3 methyltransferase controls DNA methylation in *Neurospora crassa*. *Nature* **414**: 277-283,
- Tanis PJ, Nieweg OE, Valdes Olmos RA, Th Rutgers EJ, Kroon BB (2001). History of sentinel node and validation of the technique. *Breast Cancer Res* **3**: 109-12.
- Tate PH, Bird AP (1993). Effects of DNA methylation on DNA-binding proteins and gene expression. *Curr Opin Genet Dev* **3**: 226-231,
- Tlsty TD, Crawford YG, Holst CR, Fordyce CA, Zhang J, McDermott K, Kozakiewicz K, and Gauthier ML (2004). Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis. *J Mammary Gland Biol Neoplasia* **9**, 263–274.
- Toyota M, Ahuja N, Suzuki H et al. (1999). Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. *Cancer Res.* **59**: 5438-5442.
- Trievel RC (2004). Structure and function of histone methyltransferases. *Crit Rev Eukaryot Gene Expr* **14**: 147-169.
- Tsou JA, Hagen JA, Carpenter CL, et al (2002). DNA methylation analysis: A powerful new tool for lung cancer diagnosis. *Oncogene* **21**: 5450-5461.
- Van Lint C, Emiliani S, Verdin E. (1996). The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. *Gene Expr* **5**: 245–53.
- Verma M (2003). Viral genes and methylation. *Ann N Y Acad Sci* **983**: 170-180.
- Visvader JE (2009). Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. *Genes Dev* **23**: 2563-77.

- Vleminckx K, Vakaet L Jr, Mareel M, Fiers W and van Roy F (1991). Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. *Cell* **66**: 107-119.
- Walker AR, Adam FI, Walker BF (2004). Breast cancer in black African women: a changing situation. *J R Soc Promot Health* **124**: 81-5.
- Walker AR, Adam FI, Walker BF (2004). Breast cancer in black African women: a changing situation. *J R Soc Promot Health* **124**: 81-5.
- Wang C, Fu M, Mani S, Wadler S, Senderowicz AM, Pestell RG (2001). Histone acetylation and the cell-cycle in cancer. *Front Biosci* **6**: D610-D629.
- Wang KY, James-Shen CK (2004). DNA methyltransferase Dnmt1 and mismatch repair. *Oncogene* **23**: 7898-7902.
- Ward R, Johnson M, Shridhar V, van Deursen J, Couch FJ (2005). CBP truncating mutations in ovarian cancer. *J Med Genet* **42**: 514-518.
- Wargovich MJ, Jimenez A, McKee K, Steele VE, Velasco M, Woods J, et al (2000). Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. *Carcinogenesis* **21**: 1149-55.
- Weber BL, Garber JE (1993). Family history and breast cancer. Probabilities and possibilities. *JAMA* **270**: 1602-3.
- Weiderpass E, Braaten T, Magnusson C, Kumle M, Vainio H, Lund E *et al* (2004). A prospective study of body size in different periods of life and risk of premenopausal breast cancer. *Cancer Epidemiol Biomarkers Prev* **13**: 1121-7.
- Welch DR, Steeg PS, Rinker-Schaeffer CW (2000). Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. *Breast Cancer Research* **2** (6): 408-416.
- Widschwendter M, Berger J, Hermann M, Muller HM, Amberger A, Zeschnigk M, et al (2000). Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. *J Natl Cancer Inst* **92**: 826-32.
- Widschwendter M, Jones PA (2002). DNA methylation and breast carcinogenesis. *Oncogene* **21** (35): 5462-5482.
- Widschwendter M, Jones PA (2002). The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Commentary re: J Kwong et al., Promoter

hypermethylation of multiple genes in nasopharyngeal carcinoma. *Clin Cancer Research* **8**: 131–7,

Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Muller-Holzner E, Jones PA, Laird PW (2004). Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. *Cancer Res*, **64**: 3807-3813.

Woodcock DM, Linsenmeyer ME, Doherty JP & Warren WD (1999). DNA methylation in the promoter region of the p16 (CDKN2/ MTS-1/INK4A) gene in human breast tumours. *British Journal of Cancer* **79**: 251–256.

Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J *et al* (1995). Identification of the breast cancer susceptibility gene BRCA2. *Nature* **378**: 789-92.

Worsham MJ, Raju U, Lu M, Kapke A, Botttrel A, Cheng J *et al* (2009). Risk factors for breast cancer from benign breast disease in a diverse population. *Breast Cancer Res Treat* **118**: 1-7.

Xing E, Nie Y, Song Y, Uang G-Y *et al* (1999). Mechanism of inactivation of p14(ARF), p15(INK4b) and p16(INK4a) genes in human esophageal cell carcinoma. *Clin. Cancer Res.* **5**: 2704–2713.

Xu CF, Brown MA, Chambers JA, Griffiths B, Nicolai H, *et al* (1995). Distinct transcription start sites generate two forms of BRCA1 mRNA. *Hum Mol Genet* **4**: 2259–2264.

Xu GL, Bestor TH, Bourc'his D *et al* (1999). Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. *Nature*; **402**: 187-91.

Yang X, Yan L, Davidson NE (2001). DNA methylation in breast cancer. *Endocr Relat Cancer* **8(2)**: 115–127.

Yazici H, Bitisik O, Akisik E, Cabioglu N, Saip P, Muslumanoglu M *et al* (2000). BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients. *Br J Cancer* **83**: 737-42.

Yeo W, Wong WL, Wong N, Law BK, Tse GM, Zhong S (2005). High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumorous tissue of breast cancer. *Pathology* **37(2)**: 125–130.

- Yeole BB (2008). Trends in cancer incidence in female breast, cervix uteri, corpus uteri, and ovary in India. *Asian Pac J Cancer Prev* **9**: 119-22.
- Yoder JA, Bestor TH (1998). A candidate mammalian DNA methyltransferase related to pmt1p of fission yeast. *Hum. Mol. Genet.* **7**: 279–84.
- Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP (2002). Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. *J Mol Biol* **321**: 591–9.
- Zhu WG, Srinivasan K, Dai Z, Duan W, Druhan LJ, Ding H, Yee L, Villalona-Calero MA, Plass C, Otterson GA (2003). Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. *Mol Cell Biol*, **23**: 4056-4065.
- Zochbauer-Muller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF, Minna JD (2001). 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. *Cancer Research* **61(9)**: 3581–3585
- Zochbauer-Muller S., Fong K., Virmani A. *et al* (2001). Aberrant promoter methylation of multiple genes in non small cell lung cancer. *Cancer Res.* **61**, 249–255.
- Zou HZ et al., (2002). Detection of aberrant p16 methylation in the serum of colorectal cancer patients. *Clin Cancer Research* **8**: 188 –91.